Drugs / SP284
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02591290 | Oct 2015 → Mar 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP284 | “Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects” NCT02591290 ↗ |
| Modality | Vaccine | “Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine” NCT02591290 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular (2 doses with 8-week interval)” NCT02591290 ↗ |